A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Dose Limiting Toxicities
研究概览
简要总结
This is a study for patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to standard treatment with gemcitabine. The study will also try to identify the best dose of MK-3475 to give in combination with gemcitabine.
详细描述
This study is an open-label, non-randomized phase I study, followed by open-label non-randomized phase II study. The first cohort of patients will receive 200 milligrams (mg) of MK-3475 by intravenous infusion over a 21-day period called a cycle along with Gemcitabine 1250 mg/m2 given on Days 1 and 8 of each 21-day cycle for up to 6 cycles. Patients will be seen in the study clinic 12 times over 126 days for an evaluation of signs and symptoms that may represent drug toxicity. Patients may continue to receive MK-3475 (without gemcitabine) for up to 2 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women or men with advanced, histologically proven NSCLC.
- •Patients must have received at least one but no more than three prior systemic therapies for advanced disease.
- •Any toxicity related to prior therapies that, in the opinion of the investigator, would potentially be worsened with anti-PD1 therapy or gemcitabine should be resolved to less than Grade
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Women of childbearing potential must have a negative pregnancy test
- •Ability to give informed consent and comply with the protocol.
- •Anticipated survival minimum 3 months.
- •Prior therapy with investigational agents must have been completed at least 3 weeks prior to study enrollment.
- •Patients must have normal organ and marrow function as seen on protocol-defined blood test results
- •Archived tumor tissue (minimum of 8 slides for paraffin-embedded tumor tissue) available
- •Measurable disease by RECIST 1.1 criteria.
- •Treated brain metastases will be allowed, provided they are asymptomatic.
- •Radiation for symptomatic lesions outside the Central nervous system (CNS) must have been completed at least 2 weeks prior to study enrollment.
排除标准
- •Prior therapy with any anti-PD-1, anti-PD-L1, or anti-CTLA4 antibody.
- •Prior therapy with gemcitabine.
- •Prior complications from radiation, such as history of radiation pneumonitis or pulmonary edema that, in the opinion of the investigator, may have risk of increasing toxicity with anti-PD1 therapy.
- •Active autoimmune disease except vitiligo or stable hypothyroidism.
- •Active and ongoing steroid use, except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, cardiopulmonary disease (COPD), allergic rhinitis).
- •Active other malignancy, except for controlled basal cell skin carcinoma.
- •HIV positive and/or Hepatitis B or C positive.
- •Other medical or psychiatric conditions that in the opinion of the Principal Investigator would preclude safe participation in this protocol.
研究组 & 干预措施
MK-3475 + Gemcitabine
200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
干预措施: MK-3475 (Drug)
MK-3475 + Gemcitabine
200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
干预措施: Gemcitabine (Drug)
结局指标
主要结局
Dose Limiting Toxicities
时间窗: 126 Days (six 21-day cycles)
Patients are seen in clinic 12 times over 126 days to determine any changes in signs or symptoms that may represent drug toxicity. Drug toxicity is defined as events that required holding or delaying treatment.
次要结局
- Disease Response(up to 2 years)
- Progression Free Survival(2 years)
- Overall Survival(Every 12 weeks (up to 2 years))